Biomarkers, Neurodevelopment and Preterm Infants
Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants
Sponsor: Albert Einstein College of Medicine
Terminated
Difficulty recruiting patients
Other terminated trials from Albert Einstein College of Medicine
- Mandible; Deformity · Phase NA · Jan 2024
- Stage IIA Breast Cancer · Phase NA · Oct 2023
- Cancer · Phase PHASE2 · May 2023
- Cancer · Phase PHASE2 · May 2023
- Alzheimer Disease · Phase EARLY_PHASE1 · Jan 2023
See all terminations from Albert Einstein College of Medicine
This observational or N/A phase trial investigates Epigenetic Changes and Neurodevelopmental Disorder and is currently terminated or withdrawn. Albert Einstein College of Medicine leads this study, which shows 15 recorded versions since 2015 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 10 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
May 2019 — Nov 2020 [monthly]
Terminated
Status: Recruiting → Terminated
-
Feb 2019 — May 2019 [monthly]
Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
-
Aug 2017 — Feb 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Einstein College of Medicine
- Montefiore Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .